Solitary plasmacytomas (SP) are a rare type of tumor. They are made of abnormal plasma cells. These are called clonal plasma cells. Like multiple myeloma, solitary plasmacytoma is a cancer of plasma cells. A solitary plasmacytoma is a single tumor. The bone marrow has few or no abnormal plasma cells. In multiple myeloma, the abnormal cells grow in the bone marrow throughout the body.
Recently, the International Myeloma Working Group (IMWG) published updated recommendations to help doctors accurately diagnose, treat, and monitor solitary plasmacytomas.
What is solitary plasmacytoma?
A solitary plasmacytoma is the formation of abnormal plasma cells into a tumor. It is diagnosed as either:
Solitary bone plasmacytoma: A single tumor located within the bone.
Solitary extramedullary plasmacytoma: A single tumor located in soft tissue outside the bone.
Multiple myeloma requires systemic treatment, such as chemotherapy or targeted drugs that work throughout the entire body. Solitary plasmacytoma is treated with local therapy aimed only at the tumor, usually radiation.
Solitary plasmacytomas can progress into multiple myeloma. This means they need regular monitoring. Your risk of developing myeloma from a solitary plasmacytoma depends on different risk factors.
Catching what X-rays may miss
Traditional X-rays often lack the sensitivity needed to detect small or hidden lesions elsewhere in the body.
The updated IMWG recommendations require advanced functional imaging for diagnostic evaluation, such as:
PET/CT scans (positron emission tomography combined with a CT scan)
Whole-body magnetic resonance imaging (MRI)
Advanced imaging can identify previously undetected lesions. If the scan finds more tumors, your doctor will usually treat the disease as multiple myeloma with medicines that work throughout the body. If there are only two tumors and they are small and close together, your doctor may treat both with radiation. The tumors would be watched closely to ensure it does not spread.
The main treatment for solitary plasmacytoma is still radiotherapy
Even with the development of modern drugs for plasma cell disorders, local radiation therapy remains the primary and most effective treatment for solitary plasmacytoma. Your care team will plan the radiation for your case. The new recommendations include:
Radiation dose: A total of 40 to 50 Gy (gray, the unit for measuring radiation), split into 20 to 25 sessions to the affected area.
Technique: Modern methods, such as intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT), aim the radiation at the tumor and limit harm to nearby healthy tissue.
No added drug treatment: The IMWG does not recommend myeloma medicines during or after radiation, even for large tumors. Doctors may still use them in clinical trials or in special cases, such as when radiation is not possible.
Surgery does not replace radiation therapy for eliminating the primary tumor. Instead, surgery is reserved for urgent mechanical complications, such as stabilizing bone fractures or relieving spinal cord compression caused by tumor pressure.
Long-term follow-up for solitary plasmacytoma
Careful long-term monitoring after radiation therapy helps medical teams confirm treatment response and catch any early signs of recurrence or disease progression. This may include:
A PET/CT scan or whole-body MRI 6 to 9 months after radiation. Ideally you would have the same type of scan you had at diagnosis. Scans done earlier can look abnormal while the area heals. If this scan shows complete remission, your doctor will suggest repeating the scan once a year for the first 5 years.
Blood tests for monoclonal protein (M-protein) every 3 to 6 months and urine tests every 6 to 12 months. The M-protein can take months to go away after radiation. If it stays, your doctor will watch you more closely, but that alone is not a reason to start drug treatment.
Watching for any changes
Living with or recovering from a solitary plasmacytoma requires ongoing check-ups. Visit your doctor if you notice any of these symptoms:
New or worsening bone pain (especially pain linked to movement or inflammation)
New neurological symptoms (such as numbness, tingling, or weakness)
Unexpected changes in routine blood or urine lab results
Because systemic disease can develop over time, close follow-up that combines lab tests and imaging helps detect relapses early and adjust treatment plans.
Keep track of your health with HealthTree
To learn more about plasma cell disorders, disease management, and treatment updates, visit the HealthTree website. And create an account to keep track of your health with a Personal Health Record.
Source:
International Myeloma Working Group Guidelines on Solitary Plasmacytoma
